interferon betab cytokin interferon famili use treat relapsingremit secondaryprogress form multipl sclerosi ms approv use first ms event close relat interferon beta also indic ms similar drug profil interferon beta balanc express pro antiinflammatori agent brain reduc number inflammatori cell cross blood brain barrier overal therapi interferon beta lead reduct neuron inflamm moreov also think increas product nerv growth factor consequ improv neuron surviv interferon betab avail inject form caus skin reaction inject site may includ cutan necrosi skin reaction vari great clinic present usual appear within first month treatment albeit frequenc import diminish six month treatment skin reaction preval woman mild skin reaction usual imped treatment wherea necros appear around patient lead discontinu therapi also time visibl dent inject site due local destruct fat tissu know lipoatrophi may develop interferon subclass cytokin produc bodi ill influenza order help fight infect respons mani symptom influenza infect includ fever muscl ach fatigu headach mani patient report influenzalik symptom hour take interferon beta usual improv within hour symptom relat temporari increas cytokin reaction tend disappear month treatment symptom treat overthecount nonsteroid antiinflammatori drug ibuprofen reduc fever pain anoth common transient secondari effect interferonbeta function deterior alreadi exist symptom diseas deterior similar one produc ms patient due heat fever stress uhthoff phenomenon usual appear within hour treatment common initi month treatment may last sever day symptom special sensit worsen spastic interferonbeta also reduc number white blood cell leukopenia lymphocyt lymphopenia neutrophil neutropenia well affect liver function case effect nondanger revers cessat reduct treatment nevertheless recommend patient monitor laboratori blood analysi includ liver function test ensur safe use interferon injectionsit reaction mitig rotat inject site use one medic requir less frequent inject side effect often oner enough mani patient ultim discontinu take interferon glatiram acet compar diseasemodify therapi requir regular inject earli clinic present relapsingremitt multipl sclerosi clinic isol syndrom cis singl attack singl symptom cis subacut attack suggest demyelin patient fulfil criterion diagnosi multipl sclerosi treatment interferon initi attack decreas risk develop clinic definit ms medic modest effect decreas number attack relapsingremitt multipl sclerosi reduc accumul brain lesion measur use gadoliniumenh magnet reson imag mri interferon reduc relaps approxim safe profil make firstlin treatment nevertheless patient respons therapi know ms patient nonrespons beta interferon classifi genet pharmacolog pathogenet nonrespond one factor relat nonrespond presenc high level interferon beta neutral antibodi interferon therapi special interferon betab induc product neutral antibodi usual second month treatment treat patient moreov subset rrm patient special activ ms sometim call rapid worsen ms normal nonrespond interferon betab studi longterm effect drug need datum effect interferon indic earlyiniti longterm therapi safe relat well outcom recent datum suggest interferon beta hasten disabl interferon exacerb thmediat inflammatori diseas betaferonbetaseron market today bayer pharma origin schere ag berlex north america part bayer pharm novarti also introduc extavia new brand interferon betab